Fabry Disease
Search For A Disorder
References
Arends M, Wijburg FA, Wanner C, Vaz FM, van Kuilenburg ABP, Hughes DA, Biegstraaten M, Mehta A, Hollak CEM, Langeveld M. Favourable effect of early versus late start of enzyme replacement therapy on plasma globotriaosylsphingosine levels in men with classical Fabry disease. Mol Genet Metab. 2017 May 4. pii: S1096-7192(17)30156-7.
Ersoz MG, Ture G. Cilioretinal artery occlusion and anterior ischemic optic neuropathy as the initial presentation in a child female carrier of Fabry disease. Int Ophthalmol. 2017 Mar 9. doi: 10.1007/s10792-017-0495-5. [Epub ahead of print].
El Dib R, Gomaa H, Carvalho RP, Camargo SE, Bazan R, Barretti P, Barreto FC. Enzyme replacement therapy for Anderson-Fabry disease. Cochrane Database Syst Rev. 2016 Jul 25;7:CD006663. doi: 10.1002/14651858.CD006663.pub4. Review.
van der Tol L, Svarstad E, Ortiz A, Tondel C, Oliveira JP, Vogt L, Waldek S, Hughes DA, Lachmann RH, Terryn W, Hollak CE, Florquin S, van den Bergh Weerman MA, Wanner C, West ML, Biegstraaten M, Linthorst GE. Chronic kidney disease and an uncertain diagnosis of Fabry disease: Approach to a correct diagnosis. Mol Genet Metab. 2014 Aug 20. [Epub ahead of print].
Juan P, Hernan A, Beatriz SA, Gustavo C, Antonio M, Eduardo T, Raul D, Margarita L, Mariana B, Daniela G, Marina S. Fabry Disease: Multidisciplinary Evaluation After 10 Years of Treatment with Agalsidase Beta. JIMD Rep. 2014 May 22. [Epub ahead of print].
Feustel A, Hahn A, Schneider C, Sieweke N, Franzen W, Gunduz D, Rolfs A, Tanislav C. Continuous cardiac troponin I release in fabry disease. PLoS One. 2014 Mar 13;9(3):e91757. doi: 10.1371/journal.pone.0091757. eCollection 2014.
Keating GM. Agalsidase alfa: a review of its use in the management of fabry disease. BioDrugs. 2012 Oct 1;26(5):335-54.
Waldek S, Patel MR, Banikazemi M, Lemay R, Lee P. Life expectancy and cause of death in males and females with Fabry disease: findings from the Fabry Registry. Genet Med. 2009 Nov; 11(11):790-6.
Nguyen TT, Gin T, Nicholls K, Low M, Galanos J, Crawford A. Ophthalmological manifestations of Fabry disease: a survey of patients at the Royal Melbourne Fabry Disease Treatment Centre. Clin Experiment Ophthalmol. 2005 Apr;33(2):164-8.
Beck M, Ricci R, Widmer U, Dehout F, de Lorenzo AG, Kampmann C, Linhart A,
Sunder-Plassmann G, Houge G, Ramaswami U, Gal A, Mehta A. Fabry disease: overall effects of agalsidase alfa treatment. Eur J Clin Invest. 2004 Dec;34(12):838-44.
Orssaud C, Dufier J, Germain D. Ocular manifestations in Fabry disease: a survey of 32 hemizygous male patients. Ophthalmic Genet. 2003 Sep;24(3):129-39.